# Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human Brain

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.1001/jama.2009.351</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:33471156">http://nrs.harvard.edu/urn-3:HUL.InstRepos:33471156</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
Modafinil is a wake-promoting medication used in the treatment of narcolepsy and other sleep disorders. Modafinil may enhance cognition and is used off-label for the treatment of cognitive dysfunction in some psychiatric disorders (ie, schizophrenia, attention-deficit/hyperactivity disorder [ADHD]).

Moreover, modafinil is increasingly being diverted for nonmedical use by healthy individuals with the expectation that it will improve cognitive performance. Although modafinil apparently has very low abuse liability (low reinforcing effects) in non–drug abusing individuals, the Physicians’ Desk Reference cautions that it can produce psychoactive and euphoric effects typical of central nervous system stimulant drugs, and there is debate surrounding its potential for abuse.

The mechanisms of action of modafinil are not well understood but are believed to differ from those of stimulant...
medications (methylphenidate and amphetamine), which increase dopamine in brain by targeting the dopamine transporters. It is theorized that modafinil's effects in the brain involve hypocretin, histamine, epinephrine, γ-aminobutyric acid, and glutamate. However, there is mounting preclinical evidence that dopamine is involved. For example, mice lacking dopamine transporters do not respond to the wake-promoting effects of modafinil, and this is also true for mice lacking D₁ and D₂ receptors. Microdialysis studies have also reported that modafinil increases extracellular dopamine. In addition, a recent imaging study in anesthetized monkeys documented significant occupancy of dopamine transporters by intravenously administered modafinil. This latter study also reported significant occupancy of norepinephrine transporters by modafinil, which in conjunction with a recent functional magnetic resonance imaging study showing that modafinil decreased activity in the locus coeruleus, highlights a role for norepinephrine in modafinil's effects.

The growing use of modafinil in clinical medicine and as a cognitive enhancing agent and the uncertainties surrounding the mechanisms underlying its pharmacological effects highlight the need to better understand its mechanisms of action. Of particular relevance is the need to resolve the question of whether modafinil at the doses used therapeutically increases dopamine in the human brain. This is relevant because drugs that increase dopamine in brain, particularly those that increase dopamine in the nucleus accumbens, a brain region critical for the rewarding effects of drugs of abuse, have the potential for being diverted, and repeated use by individuals who are vulnerable can result in addiction. We tested the hypothesis that modafinil, at therapeutically relevant doses, would elevate extracellular dopamine in the human brain by blocking the dopamine transporter. We tested 2 doses of modafinil: 200 mg, the dose recommended for narcolepsy, and 400 mg, a dose shown to be beneficial for the treatment of ADHD.

**METHODS**

**Participants**

This study was carried out at Brookhaven National Laboratory from 2007 to 2008 and approved by the local institutional review board (Committee on Research Involving Human Subjects, State University of New York at Stony Brook). Written informed consent was obtained from all participants after the study had been fully explained to them. Participants were paid for their participation and received information on potential adverse effects of modafinil during the consenting process. Participants were initially screened by phone and if appropriate were referred for evaluation by a neurologist (F.T.) who ensured that they met study criteria.

Ten healthy men with a mean (SD) age of 34 (7.1) years (range, 23–46 years) who responded to a local newspaper advertisement were selected for the study out of 50 screened participants. Inclusion criteria were male sex, nonsmoking, ability to understand and give informed consent, and age of 18 to 50 years. Excluded were those participants who were urine positive for psychoactive drugs (including phencyclidine, cocaine, amphetamine, opiates, barbiturates, benzodiazepines, and tetrahydrocannabinol); those with clinically significant abnormal laboratory values; those with history of or current medical illness or neurological or psychiatric disease (including mood fluctuations); those who had used psychoactive medications in the past month; those who had experienced head trauma with loss of consciousness longer than 30 minutes; and those with a history of or current substance abuse (including nicotine).

**Radiotracer Synthesis and PET Studies**

[11C]Cocaine was synthesized from norcocaine (National Institute on Drug Abuse Research Technology Branch, Rockville, Maryland) according to the literature method. Radiochemical purity was greater than 98%, mean (SD) specific activity was 61.8 (34.3) MBq/nmol at end of synthesis, and the mean (SD) injected dose was 258 (21.1) MBq. Dynamic positron emission tomography (PET) scans were obtained using a PET/CT scanner (Siemens, Knoxville, Tennessee) on a single day after waiting 30 minutes following injection. The [11C]raclopride first, whereas the rest of the participants received the [11C]cocaine first. We completed giving the 200-mg group before the 400-mg group.

Participants were scanned 4 different times over a 2-day period (at least 1 week apart from each other); on one day they underwent 2 scans with [11C]cocaine, and on another day they underwent 2 scans with [11C]raclopride. The order of radiotracers was varied to control for potential ordering effects as follows: for the 200-mg group, 3 participants received the [11C]raclopride first and for the 400-mg group, 2 participants received the [11C]raclopride first, whereas the rest of the participants received the [11C]cocaine first. We completed giving the doses and performing the scans with the 200-mg group before the 400-mg group. On each day, the first scan was done 2 hours after administration of placebo and the second scan was done 2 hours after administration of modafinil, which was given immediately on completion of the first scan.

Participants were blinded to whether they would receive placebo or modafinil or the dose received. Measures of modafinil concentration in plasma were obtained at 2 hours after modafinil (corresponding to the time of scan initiation) and analyzed using high-performance liquid chromatography with spectrophotometric detection (Analytical Psychopharmacology Laboratories, Nathan Kline Institute, Orangeburg, New York). The placebo plasma sample served as a blank for the measurements.
electron emission tomographic (PET) imaging was carried out on a Siemens HR+ high-resolution, whole-body PET scanner (4.5 × 4.5 × 4.8 mm full width at half maximum at center of field of view) in three-dimension acquisition mode in 63 planes (Siemens Medical Solutions Inc, Knoxville, Tennessee). For all scans, a transmission scan was obtained with a germanium 68 rotating rod source prior to the emission scan to correct for attenuation. Scanning was carried out for 54 minutes with the following time frames: 1 × 10 seconds, 12 × 5 seconds, 1 × 20 seconds, 1 × 30 seconds, 4 × 60 seconds, 4 × 120 seconds, and 8 × 300 seconds.

[11C]Raclopride was synthesized by the literature method. Radiochemical purity was greater than 98%, mean (SD) specific activity was 67.7 (42.9) MBq/nmol at time of injection, and the mean (SD) injected dose was 235 (29.6) MBq. Scanning was carried out for 60 minutes with the following time frames: 1 × 10 seconds, 12 × 5 seconds, 1 × 20 seconds, 1 × 30 seconds, 8 × 60 seconds, and 10 × 300 seconds. Arterial blood was collected over the course of the study, and plasma was obtained and analyzed for the fraction of carbon 11 present as the parent radiotracer.

**Drug Effect Ratings**

Recordings for heart rate and blood pressure were obtained continuously throughout the study. Behavioral effects were evaluated with 2 types of scales. Analog scales assessed self-reports for the descriptors alert, anxious, high, mood, restless, and tired, on a scale of 1 (felt nothing) to 10 (felt intensely). The Profile of Mood Scales is a scale widely used to assess the effects of drugs on mood states, which were rated on a 10-point scale ranging from 1 (not at all) to 10 (extremely). These measures were obtained prior to and at 2 hours and 3 hours after administration of placebo or of modafinil.

**Image Processing and Parameter Estimation**

To obtain as high a signal as possible for anatomical region identification, the time frames were summed over the entire scanning period. The summed images were resliced along the anterior commissure–posterior commissure line and parameter estimation was performed separately and then averaged after ensuring that there were no significant laterality effects.

Dopamine receptors and dopamine transporters are highly concentrated in caudate, putamen, and nucleus accumbens whereas their concentration in cerebellum is negligible. Thus, the cerebellum serves as a reference region to control for nonspecific binding. Time-activity curves along with the time course of the arterial concentration of the radiotracer were used to calculate \( K_1 \), the transfer constant from plasma to brain, and the distribution volumes (\( V_T \)), which correspond to the equilibrium measurement of the ratio of tissue to plasma concentration in the caudate, putamen, nucleus accumbens, and cerebellum.

**Table.** Model Terms, \( K_1 \), and Binding Potential for \([11C]\)Raclopride and \([11C]\)Cocaine for the Placebo and Modafinil Conditions

<table>
<thead>
<tr>
<th>Model Term</th>
<th>Mean (SD)</th>
<th>( P ) Value</th>
<th>Mean Difference Between Placebo and Modafinil (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>([11C])Raclopride</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( K_1 ), mL/cc/min</td>
<td>Placebo</td>
<td>Modafinil</td>
<td>( P ) Value</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>0.112 (0.033)</td>
<td>0.103 (0.015)</td>
<td>.30</td>
</tr>
<tr>
<td>Caudate</td>
<td>0.101 (0.015)</td>
<td>0.096 (0.013)</td>
<td>.36</td>
</tr>
<tr>
<td>Putamen</td>
<td>0.121 (0.018)</td>
<td>0.116 (0.013)</td>
<td>.38</td>
</tr>
<tr>
<td>( BP_{ND} )</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caudate</td>
<td>2.68 (0.49)</td>
<td>2.53 (0.56)</td>
<td>.01</td>
</tr>
<tr>
<td>Putamen</td>
<td>3.44 (0.49)</td>
<td>3.22 (0.55)</td>
<td>.001</td>
</tr>
<tr>
<td>Nucleus accumbens</td>
<td>2.89 (0.46)</td>
<td>2.31 (0.66)</td>
<td>.02</td>
</tr>
<tr>
<td>([11C])Cocaine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( K_1 ), mL/cc/min</td>
<td>Placebo</td>
<td>Modafinil</td>
<td>( P ) Value</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>0.40 (0.07)</td>
<td>0.44 (0.07)</td>
<td>.01</td>
</tr>
<tr>
<td>Caudate</td>
<td>0.43 (0.08)</td>
<td>0.46 (0.08)</td>
<td>.01</td>
</tr>
<tr>
<td>Putamen</td>
<td>0.49 (0.10)</td>
<td>0.54 (0.11)</td>
<td>.02</td>
</tr>
<tr>
<td>( BP_{ND} )</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caudate</td>
<td>0.74 (0.11)</td>
<td>0.34 (0.19)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Putamen</td>
<td>0.95 (0.06)</td>
<td>0.50 (0.09)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Nucleus accumbens</td>
<td>0.86 (0.16)</td>
<td>0.52 (0.11)</td>
<td>.001</td>
</tr>
</tbody>
</table>

Abbreviations: \( BP_{ND} \), binding potential; CI, confidence interval; \( K_1 \), transfer constant from plasma to brain.

\(^a\)Paired samples \( t \) tests show that there is no significant difference between the 200-mg and 400-mg doses for any of these variables.

\(^b\)Mean differences (placebo − modafinil) and 95% confidence intervals for the combined 200-mg and 400-mg dose groups.
using graphical analysis methods for reversible systems. The ratio of the $V_t$ in the caudate, putamen, and nucleus accumbens to that in the cerebellum is referred to as the distribution volume ratio. The distribution volume ratio minus 1 corresponds to the binding potential (BPND) and is insensitive to changes in blood flow. The BPND for the caudate, putamen, and nucleus accumbens was used as an estimate of dopamine transporter availability and $D_2/D_3$ receptor availability after placebo and after modafinil. Data are expressed as means and standard deviations. There were no missing data points.

**Formation of Averaged Images**

Averaging data across participants reduces random noise, which tends to cancel while enhancing the signal, which should be additive. To make images with an improved signal-to-noise ratio, the individual time frame images for all participants in a group were averaged. To average brains of different shapes and sizes, we first normalized them to the SPM template so that all brains had corresponding structures in the same space. The blood data from each participant were also averaged for each time frame. Using the mean dynamic image (averaged over all participants in the group) and the average input (blood radioactivity) function, an average distribution volume image was created. The BPND image was created by dividing each voxel in the image by the cerebellum distribution volume and subtracting 1.

**Statistics**

The sample size was determined based on results from studies that measured dopamine transporter occupancy and dopamine changes with 20-mg oral methylphenidate. Primary outcomes were changes in dopamine $D_2/D_3$ receptor and dopamine transporter availability as measured by changes in BPND after placebo and after modafinil. Significant effects were considered for $P < .05$ (2-tail). For dopamine transporter occupancy, we predicted a mean (SD) occupancy of 50% (5%); thus, the estimated power of the paired $t$ test at the significance level of .05 (2-sided) with $n=10$ was 99%. For dopamine changes, we predicted a 6% (6%) change; thus, the statistical power to detect significance at $\alpha = .05$ (2-sided) with $n=10$ was 80%. Repeated-measures analysis of variance (ANOVA) was used to examine the modafinil effect (placebo vs modafinil), the dose effect (200 mg vs 400 mg), and the modafinil and dose interaction for $K_1$ and BPND for both $[^{11}C]$cocaine and $[^{11}C]$raclopride.

Plasma modafinil levels were compared for the 200-mg and 400-mg dose groups and for the same participant on day 1 and day 2 using repeated-measures ANOVA (fixed effect: dose groups, 200 mg vs 400 mg; repeated measures, day 1 vs day 2). Pearson product moment correlations were used to assess the association between individual plasma modafinil levels and percentage change in BPND for $[^{11}C]$cocaine and $[^{11}C]$raclopride. Repeated-measures ANOVA was also used to compare the differences between placebo and modafinil and between the 2 modafinil doses in the cardiovascular and behavioral measures. Statistical analysis was performed with SAS version 9.2 (SAS Institute Inc, Cary, North Carolina).

**RESULTS**

Modafinil significantly increased heart rate and systolic blood pressure and these effects were significant for both
doses. Repeated-measures ANOVA revealed a dose effect that showed higher increases in heart rate for 400-mg than for 200-mg modafinil (P < .05). None of the effects of modafinil on the behavioral measures were significant.

Repeated-measures ANOVA showed no significant dose effect (200 mg vs 400 mg) nor significant dose and drug (placebo vs modafinil) interaction effect for all BPND and K1 measures. Therefore in the subsequent analysis, the 200-mg and 400-mg dose groups were combined. Modafinil produced significant reductions in BPND for [11C]raclopride and for [11C]cocaine (TABLE), and this can be seen in BPND images after placebo and after modafinil for [11C]raclopride and [11C]cocaine (FIGURE 1). Modafinil decreased mean (SD) [11C]raclopride BPND in caudate (6.1% [6.5%]; 95% CI, 1.5% to 10.8%; P = .02), putamen (6.7% [4.9%]; 95% CI, 3.2% to 10.3%; P = .002), and nucleus accumbens (19.4% [20%]; 95% CI, 5% to 35%; P = .02), reflecting increases in dopamine. It also decreased [11C]cocaine BPND in caudate (53.8% [13.8%]; 95% CI, 43.9% to 63.6%; P < .001), putamen (47.2% [11.4%]; 95% CI, 39.1% to 55.4%; P < .001), and nucleus accumbens (39.3% [10%]; 95% CI, 30% to 49%; P = .001), reflecting occupancy of the dopamine transporters.

For the combined group, K1 for [11C]cocaine (but not for [11C]raclopride) was significantly elevated in cerebellum, caudate, and putamen after modafinil, indicating that the transfer of [11C]cocaine from blood to brain was elevated by modafinil (TABLE). We note K1 is related to blood flow (F) and permeability surface area product (PS) by the equation K1 = F(1 – e$$^{-\frac{PS}{F}}$$). Depending on the ratio PS/F, K1 can have values close to F (when PS is much greater than F) or close to PS (when F is much greater than PS). For [11C]raclopride, the latter condition holds because K1 is much less than blood flow (which is ~0.3 mL/min/cc). For [11C]cocaine, the former condition holds because K1 is larger and closer to typical blood flow values. Increases in cerebro blood flow from modafinil, which have been documented previously, would therefore be more likely to be seen as increases in K1 for [11C]cocaine but not for [11C]raclopride.

Plasma modafinil concentrations were compared for the 200-mg and 400-mg groups. Although the mean (SD) 400-mg group values tended to be higher (6.2 [2.6] µg/mL vs 4.3 [1.6] µg/mL), repeated-measures ANOVA (fixed effect: dose groups, 200 mg vs 400 mg; repeated measures, day 1 vs day 2) revealed that plasma modafinil concentrations did not differ significantly between doses (F1,8 = 4.36, P = .07). For the same participant, they also did not differ between day 1 and day 2 (F1,8 = 2.85, P = .13) (FIGURE 2).

There was a significant correlation between the percentage decrease in [11C]cocaine BPND and plasma modafinil concentration, which corresponded in caudate to R = .87 (P < .001) and in putamen to R = .76 (P = .01) (FIGURE 3). There were no significant correlations between the percentage decrease in [11C]raclopride BPND and the concentration of modafinil in plasma (R = −.38, P = .28, 2-sided). The correlation between modafinil-induced changes in [11C]cocaine BPND and changes in [11C]raclopride BPND was not significant for either the caudate (R = .37, P = .30) or the putamen (R = −.11, P = .76, 2-sided).

**COMMENT**

At clinically relevant doses, modafinil significantly increases dopamine in the human brain by blocking dopamine transporters. Modafinil’s binding to the dopamine transporter overlaps with the binding site of cocaine because [11C]cocaine binding in striatum was inhibited by modafinil. Along with the mounting evidence from the preclinical literature, this finding provides support for the role of dopamine in modafinil’s pharmacological actions in humans. Thus, the hypothesis of the nondopamine mechanism of action of modafinil needs to be reconsidered.

The mean (SD) reductions in [11C]raclopride and [11C]cocaine BPND after modafinil were similar to those reported for a 20-mg oral dose of methylphenidate in normal volunteers, which corresponded to about 5% (6%) for raclopride and to about 54% (5%) for [11C]cocaine. This indicates that modafinil at therapeutic doses produces elevations in brain dopamine through blockade of dopamine transporters, which are similar to those produced by therapeutic doses of methylphenidate. Even though modafinil’s affinity for dopamine transporters is low.
relative to methylphenidate (6.390 μM vs 0.025 μM⁶), the therapeutic doses are much higher for modafinil (200 mg) than for methylphenidate (20 mg).

**Drug Effects**

Two doses of modafinil (200 mg and 400 mg) were evaluated, but neither the plasma modafinil concentrations nor the dopamine transporter blockade or dopamine changes differed between the 2 doses, which may reflect the relatively small sample of the study. The lack of a dose effect is also confounded by the large participant variability in modafinil’s plasma concentrations (particularly for 1 participant in the 400-mg dose group) (Figure 2), which predicted the level of dopamine transporter occupancy (Figure 3).

The variability in plasma modafinil concentration is likely to reflect variability in metabolism of modafinil. Neither modafinil’s plasma concentration nor the level of dopamine transporter occupancy correlated with the dopamine changes. We had reported a similar finding with methylphenidate in which a correlation was found between plasma concentration and dopamine transporter occupancy, but neither plasma concentration nor dopamine transporter occupancy correlated with dopamine changes.⁶ This reflects that although plasma (and presumably brain) modafinil levels proportionally compete with [¹¹C]cocaine for binding to the dopamine transporters, decreases in [¹¹C]raclopride binding are a function of changes in extracellular dopamine, which are determined not only by dopamine transporter blockade but also by dopamine cell firing. For the same level of dopamine transporter blockade, dopamine changes will be greater when the activity of dopamine cells is high than when it is low.

Stimulant medications act as wake-promoting agents by increasing dopamine (as well as norepinephrine) in brain.⁵ Modafinil was developed with an expectation that a medication could have a nondopaminergic target for its wake-promoting effects. However, the current findings in humans, along with preclinical studies,⁶,⁷ documenting the indispensable role of dopamine in the wake-promoting effects of modafinil, support modafinil’s dopamine-enhancing effects as a mechanism for its therapeutic actions.

The dopamine-enhancing effects of modafinil in the nucleus accumbens may help explain reports of its abuse, since this pharmacological effect is considered crucial for drug reinforcement.⁹ Indeed, modafinil was shown to be self-administered in monkeys previously trained to self-administer cocaine,¹⁰ and in humans modafinil can act as a reinforcer under conditions of behavioral demand.³² However, modafinil is much less potent as a reinforcer than stimulant drugs, and reports of modafinil abuse are rare and much less frequent than those for stimulant drugs.³⁶ Nonetheless, considering the broadening use of modafinil and the results in this study showing that it increases dopamine in the nucleus accumbens at therapeutic doses, its potential for abuse should not be disregarded.

In this study, modafinil’s binding to dopamine transporters overlapped with the binding site of cocaine. This could account for the findings that modafinil interfered with the behavioral effects of cocaine.³⁷ Indeed pilot studies have reported some beneficial effects of modafinil in the treatment of cocaine addiction.³⁸

**Study Limitations**

The [¹¹C]raclopride method does not allow the exclusion of the possibility that decreases reflect down-regulation of D₁/D₃ receptors and changes in affinity⁹⁰ rather than dopamine increases. Since microdialysis studies⁸,¹¹-¹³ have shown that modafinil increases dopamine in striatum (including nucleus accumbens), this suggests that the findings in this study reflect dopamine increases. The small sample size of the study did not provide sufficient statistical power to detect dose effects. Only healthy young men were tested, which may limit generalizability to other populations. This study did not use a complete placebo design but rather used a placebo to compare the effects of modafinil on each radiotracer, which required that the placebo be given first and the modafinil second, so the possibility of an order effect cannot be ruled out. The order of modafinil doses tested was not randomized; instead the first 5 participants were tested with 200 mg and the subsequent 5 with 400 mg. However, it is unlikely that this affected the results obtained. This study did not measure a clinical outcome, so further studies are necessary to assess this.

**CONCLUSION**

In this pilot study, modafinil acutely increased dopamine levels and blocked dopamine transporters in the human brain. Because drugs that increase dopamine have the potential for abuse, and considering the increasing use of modafinil for multiple purposes, these results suggest that risk for addiction in vulnerable persons merits heightened awareness.

**Author Affiliations:** National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (Drs Volkow and Telang, Mr Jayne, and Ms Muench); National Institute on Drug Abuse, Bethesda (Dr Volkow); Brookhaven National Laboratory, Upton, New York (Drs Fowler, Logan, Wang, and Hooker; Messrs Alexoff, Wong, Warner, and King; and Ms Hubbard, Carter, King, She, Xu, and Apelskog-Torres); Mount Sinai School of Medicine, New York, New York (Drs Fowler and Wang); and Departments of Chemistry (Dr Fowler) and Applied Mathematics and Statistics (Dr Zhu), State University of New York at Stony Brook.

**Author Contributions:** Dr Volkow had full access to all of the data in the study and takes full responsibility for the integrity of the data and the accuracy of the data analysis. Drs Volkow and Fowler contributed equally to this work.

**Study concept and design:** Volkow, Fowler, Wang.

**Acquisition of data:** Telang, Wang, Jayne, Hubbard, Carter, Warner, King, She, Xu, Muench, Apelskog-Torres.


**Drafting of the manuscript:** Volkow, Fowler, Alexoff, Telang, Wang, Jayne, Hooker, Wong, Hubbard, Carter, Warner, King, She, Xu, Muench, Apelskog-Torres.

**Critical revision of the manuscript for important intellectual content:** Volkow, Fowler, Logan, Zhu.

**Statistical analysis:** Zhu.

**Obtained funding:** Volkow, Fowler.

**Administrative, technical, or material support:** Telang, Wang, Jayne, Hubbard, Carter, Apelskog-Torres.

**Study supervision:** Volkow, Fowler, Wang.

**Financial Disclosures:** None reported.

**Funding/Support:** This research was carried out at Brookhaven National Laboratory under contract DE-AC02-98CH10886 with the US Department of Energy with infrastructure support from its Office of Biological and Environmental Research. Support was also provided by grant K05DA020001 (J.S.F.).

©2009 American Medical Association. All rights reserved.

(Reprinted) JAMA, March 18, 2009—Vol 301, No. 11 1153
EFFECTS OF MODAFINIL ON DOPAMINE AND DOPAMINE TRANSPORTERS

from the National Institutes of Health, the National Institute on Alcohol Abuse and Alcoholism Intramural research program, grant F32EB997320 (J.M.H.) from the National Institute of Biomedical Imaging and Bioengineering, and grant MO1RR10710 from the General Research Clinical Centers. A Goldhaber distinguished fellowship provided support for Dr Hooker.

Role of the Sponsor: The funding agencies had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.

Previous Presentation: Presented at the 55th Annual Society of Nuclear Medicine meeting; June 16, 2008; New Orleans, Louisiana.

Additional Contributions: David Schlyer, PhD, and Michael Schueller, PhD, Brookhaven National Laboratory, assisted with cyclotron operations. Joan Terry, and Hai-Dee Lee, MS, Brookhaven National Laboratory, assisted with clinical research center operations. Nikhil Pujari, BS, State University of New York at Stony Brook, helped with the image analysis, and Linda Thomas, BS, National Institutes of Health, provided editorial assistance. None received compensation outside of their salaries. We thank the individuals who volunteered for these studies, who each received a volunteer fee.

REFERENCES


Downloaded From: http://jama.jamanetwork.com/ by a Harvard University User on 03/25/2014